SCHEMBL405087

SCHEMBL405087

CCOc1ccc(C(=O)Nc2cccc(F)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.69
RAB9A P51151 4/20 0.69
LMNA P02545 4/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
HPGD P15428 1/20 0.62
TP53 P04637 3/20 0.62
ALDH1A1 P00352 2/20 0.62
KDM4E B2RXH2 1/20 0.60
CYP1A2 P05177 1/20 0.60
MAPT P10636 1/20 0.60
NR1H4 Q96RI1 3/20 0.58
RECQL P46063 1/20 0.57
POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4104448 0.85 ALDH1A1 (0.70) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL404366 0.85 NPC1 (0.72) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL28393105 0.83 NPC1 (0.58) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL27180667 0.83 THRB (0.64) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL30926804 0.83 THRB (0.64) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL10294777 0.83 NPC1 (0.79) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL6579950 0.82 NPC1 (0.73) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL4104631 0.81 KMT2A (0.59) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL5943878 0.80 NPC1 (0.63) NPC1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL14372400 0.80 CA1 (0.66) NPC1RAB9ALMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150105433-A1 TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM THE UAB RESEARCH FOUNDATION 2015-04-16 US disclosed
US-20150105433-A1 TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM THE UAB RESEARCH FOUNDATION 2015-04-16 US disclosed
US-20120065247-A1 MODULATING IRES-MEDIATED TRANSLATION DISCOVERYBIOMED, INC. (US) 2012-03-15 US disclosed
US-20120065247-A1 MODULATING IRES-MEDIATED TRANSLATION DISCOVERYBIOMED, INC. (US) 2012-03-15 US disclosed
WO-2010111653-A2 MODULATING IRES-MEDIATED TRANSLATION THE UAB RESEARCH FOUNDATION (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065247-A1 MODULATING IRES-MEDIATED TRANSLATION EIF2AK2, EIF4EBP1, EIF4E NPC1 2519/4885RAB9A 2106/4885LMNA 2248/4885
US-20150105433-A1 TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM EIF2AK2, RPS25, RPL35 NPC1 859/4885RAB9A 2752/4885LMNA 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.